Haemophilus influenzae infection future or investigational therapies
|
Haemophilus influenzae infection Main page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Future and Investigational Therapies
Elimination of persistent Hib disease in the United States. Currently available conjugate vaccines differ in immuno-genicity in very young children and possibly in duration of antibody persistence, raising questions about long-term efficacy (>5 years), optimal use, and schedules. Monitoring the possible emergence of disease due to other serotypes. Problems with serotyping of H. influenzae in state health departments. Development of rapid molecular assays for detection and molecular subtyping of all Hi strains. The cost of Hib conjugate vaccines has limited their use in developing countries even though Hib is a major cause of morbidity and mortality.